Hemophilia B replacement therapy drugs
Author:
Affiliation:

Clc Number:

Fund Project:

National Natural Science Foundation of China (No. 81500108).

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Cited by
  • |
  • Materials
  • |
  • Comments
    Abstract:

    Hemophilia B is an X chromosome linked hereditary hemorrhagic disease, which is caused by the lose function mutation of factor IX (FIX), and significantly affects the patients’ lifespan and life quality. The severity of hemophilia B depends on the FIX level in the plasma. By referring to the relevant literatures, we reviewed and summarized hemophilia B replacement therapies. Specifically, we focus on recombinant factor IX products on the market and those in the pipeline, especially on the long-acting factor IX drugs, to provide the basis for researches of new hemophilia B drugs.

    Reference
    Related
    Cited by
Get Citation

严红,曾凡一. 血友病B替代治疗药物研究现状及进展[J]. Chinese Journal of Biotechnology, 2016, 32(2): 164-171

Copy
Related Videos

Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Received:May 29,2015
  • Revised:
  • Adopted:
  • Online: January 26,2016
  • Published:
Article QR Code